A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Sekeres, Mikkael A.; Gundacker, Holly; Lancet, Jeffrey; Advani, Anjali; Petersdorf, Stephen; Liesveld, Jane; Mulford, Deborah; Norwood, Tom; Willman, Cheryl L.; Appelbaum, Frederick R.; List, Alan F.

doi:10.1182/blood-2011-02-337303

Cited by 80Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesProtein Degradation and Inhibitors

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Open access

Sekeres, Mikkael A., Gundacker, Holly, Lancet, Jeffrey, Advani, Anjali, Petersdorf, Stephen, Liesveld, Jane, Mulford, Deborah, Norwood, Tom +3 more·2011·Blood

DOI 10.1182/blood-2011-02-337303PMC PMC3142897

Open this paper in CoChat — free account

Abstract

Older acute myeloid leukemia (AML) patients with a chromosome 5q deletion have poor outcomes with conventional chemotherapy. This phase 2 study explored the safety and efficacy of single-agent lenalidomide in previously untreated older AML patients with del(5q) who declined standard chemotherapy. Patients were treated with lenalidomide 50 mg daily for 28 days as induction therapy and 10 mg daily for 21 days of a 28-day cycle as maintenance until disease progression or unacceptable toxicity. Among 37 evaluable patients, the median age was 74 years (range, 60-94), 21 (57%) were female, 19 (51%) had prior myelodysplastic syndrome, and 30 (81%) had pretreatment cytogenetic studies evaluated centrally. Six had isolated del(5q), 1 had del(5q) and +8, 23 had complex cytogenetics, and 7 others had del(5q) identified locally. Fourteen patients (38%) completed induction therapy: 7 patients died during induction therapy, 8 had disease progression, 7 had nonfatal adverse events, and 1 entered hospice. Eight patients started maintenance therapy. Five patients (14%) achieved a partial or complete response, 2 with isolated del(5q) and 3 with complex cytogenetics. Relapse-free survival was 5 months (range, 0-19). Median overall survival was 2 months for the entire population. In conclusion, lenalidomide as a single agent has modest activity in older del(5q) AML patients. Southwest Oncology Group Study S0605 is registered at www.clinicaltrials.gov as NCT00352365.

Integrity signals

Registry

Crossref · 10.1182/blood-2011-02-337303

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Despite 5q-MDS often progressing into AML and many AML patients harboring 5q abnormalities, targeting CK1α with lenalidomide showed only a modest therapeutic effect.
“Surprisingly, despite 5q-MDS often progressing into AMl and many AMl patients harboring 5q abnormalities, targeting cK1α with lenalidomide showed only a modest therapeutic effect (Sekeres et al. 2011).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Sekeres et al. 2011
Altered regulation of gene expression as a result of IKZF1 degradation might also contribute to responsiveness of myeloid malignancies to lenalidomide.
“Thus, altered regulation of gene expression as a result of IKZF1 degradation might also contribute to responsiveness of myeloid malignancies to lenalidomide97,101.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [101]

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,232 · see citing works
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158 · see citing works
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686 · see citing works
Self-citation
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137 · see citing works
Age and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H. M., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,352 · see citing works
Self-citation
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · see citing works
Self-citation
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961 · see citing works
Self-citation
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Ebert, B. L., Pretz, J. L., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E. C., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 925 · see citing works
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
Grimwade, D. J. (2001) · Blood · doi:10.1182/blood.v98.5.1312 · Cited by 917 · see citing works
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
Leith, C. P., Kopecky, K. J., Godwin, J. E., McConnell, T. S., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997) · Blood · doi:10.1182/blood.v89.9.3323 · Cited by 859 · see citing works
Self-citation
A Southwest Oncology Group study
Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773 · see citing works
A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619 · see citing works
Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L., & Schiffer, C. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322503 · Cited by 447 · see citing works
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 437 · see citing works
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M. E., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 383 · see citing works
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
Baer, M. R., George, S. L., Dodge, R. K., O’Loughlin, K. L., Minderman, H., Caligiuri, M. A., Anastasi, J., Powell, B. L., Kolitz, J. E., Schiffer, C. A., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1224.h81602001224_1224_1232 · Cited by 366 · see citing works
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
Farag, S. S., Archer, K. J., Mrózek, K., Ruppert, A. S., Carroll, A. J., Vardiman, J. W., Pettenati, M. J., Baer, M. R., Qumsiyeh, M. Β., Koduru, P. R. K., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4354 · Cited by 332 · see citing works
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
Rowe, J. M., Neuberg, D. S., Friedenberg, W. R., Bennett, J. M., Paietta, E. M., Makary, A. Z., Liesveld, J. L., Abboud, C. N., Dewald, G. W., Hayes, F. A., et al. (2003) · Blood · doi:10.1182/blood-2003-05-1686 · Cited by 277 · see citing works
Self-citation
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Tilly, H., Castaigné, S., Bordessoule, D., Casassus, P., Prisé, P. Y. L., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259 · see citing works
Cancer and Leukemia Group B
National Cancer Institute (2020) · Definitions · doi:10.32388/b2g8ub · Cited by 217 · see citing works
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng, W., Chen, X., Rocha, K., Epling‐Burnette, P. K., Djeu, J. Y., Liu, Q., Byrd, J. C., Sokol, L., Lawrence, N., Pireddu, R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811267106 · Cited by 192 · see citing works
Self-citation
Acute Myeloid Leukemia
Stone, R. M., O'Donnell, M. R., & Sekeres, M. A. (2004) · Hematology · doi:10.1182/asheducation-2004.1.98 · Cited by 184 · see citing works
Self-citation
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
Adès, L., Boehrer, S., Prébet, T., Beyne‐Rauzy, O., Legros, L., Ravoet, C., Dreyfus, F., Stamatoullas, A., Chaury, M., Delaunay, J., et al. (2008) · Blood · doi:10.1182/blood-2008-08-175778 · Cited by 151 · see citing works
Adhesion of human platelets to serum amyloid A
Urieli-Shoval, S., Shubinsky, G., LINKE, R. P., Fridkin, M., Tabi, I., & Matzner, Y. (2002) · Blood · doi:10.1182/blood.v99.4.1224 · Cited by 108 · see citing works
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
Fehniger, T. A., Uy, G. L., Trinkaus, K., Nelson, A. D., Demland, J., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., Westervelt, P., DiPersio, J. F., et al. (2011) · Blood · doi:10.1182/blood-2010-07-297143 · Cited by 107 · see citing works
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities
Ravandi, F., Issa, J. J., Garcia‐Manero, G., O'Brien, S. M., Pierce, S. A., Shan, J., Borthakur, G. M., Verstovšek, S., Faderl, S. H., Cortes, J. E., et al. (2009) · Cancer · doi:10.1002/cncr.24661 · Cited by 91 · see citing works
Trends in the Treatment of Acute Myeloid Leukaemia in the Elderly
Lang, K. M., Earle, C. C., Foster, T. S., Dixon, D., van Gool, R., & Menzin, J. (2005) · Drugs & Aging · doi:10.2165/00002512-200522110-00004 · Cited by 89 · see citing works
Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
Blum, W., Klisovic, R. B., Becker, H., Yang, X., Rozewski, D. M., Phelps, M. A., Garzon, R., Walker, A., Chandler, J. C., Whitman, S. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3339 · Cited by 87 · see citing works
Stress-induced premature senescence mediated by a novel gene, SENEX, results in an anti-inflammatory phenotype in endothelial cells
Coleman, P. R., Hahn, C. N., Grimshaw, M. J., Lü, Y., Li, X., Brautigan, P. J., Beck, K., Stocker, R., Vadas, M. A., & Gamble, J. R. (2010) · Blood · doi:10.1182/blood-2009-11-252700 · Cited by 59 · see citing works
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher‐risk myelodysplastic syndromes
Sekeres, M. A., O’Keefe, C. L., List, A. F., Paulic, K., Afable, M. G., Englehaupt, R. K., & Maciejewski, J. P. (2010) · American Journal of Hematology · doi:10.1002/ajh.21891 · Cited by 46 · see citing works
Self-citation
Treatment of deletion 5q acute myeloid leukemia with lenalidomide
Lancet, J. E., List, A. F., & Moscinski, L. C. (2007) · Leukemia · doi:10.1038/sj.leu.2404526 · Cited by 34 · see citing works
Self-citation
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome
Mesa, R. A., Tefferi, A., Li, C.-Y., & Steensma, D. P. (2006) · Leukemia · doi:10.1038/sj.leu.2404398 · Cited by 32 · see citing works
Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
Baz, R., Rodriguez, C. P., Fu, A. Z., Jawde, R. M. A., Kalaycio, M. E., Advani, A. S., Sobecks, R. M., & Sekeres, M. A. (2007) · Cancer · doi:10.1002/cncr.22976 · Cited by 32 · see citing works
Self-citation
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
Sugimoto, Y., Sekeres, M. A., Makishima, H., Traina, F., Visconte, V., Jankowska, A. M., Jerez, A., Szpurka, H., O’Keefe, C. L., Guinta, K. M., et al. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-4 · Cited by 26 · see citing works
Self-citation
Angiopoietin-2 in CLL
Burger, J. A. (2010) · Blood · doi:10.1182/blood-2010-04-279935 · Cited by 17 · see citing works
Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM)
Adès, L., Prébet, T., Stamatoullas, A., Récher, C., Guièze, R., Raffoux, E., Bouabdallah, K. K., Hunault, M., Wattel, E., Stalnikiewicz, L., et al. (2010) · Blood · doi:10.1182/blood.v116.21.508.508 · Cited by 17 · see citing works
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT
Ford, C. D., Asch, J. D., Konopa, K., & Petersen, F. B. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.146 · Cited by 10 · see citing works
A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial
Platzbecker, U., Haase, D. T., Braulke, F., Bug, G., Götze, K. S. S., Kuendgen, A., Röllig, C., Wermke, M., Naumann, R., Bornhäuser, M., et al. (2010) · Blood · doi:10.1182/blood.v116.21.4000.4000 · Cited by 3 · see citing works
Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q)
Sugimoto, Y., Sekeres, M. A., Makishima, H., O’Keefe, C. L., Guinta, K. M., Afable, M. G., McGraw, K. R., List, A. F., & Maciejewski, J. P. (2010) · Blood · doi:10.1182/blood.v116.21.4016.4016 · Cited by 2 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Lübbert, M., Rüter, B. H., Claus, R., Schmoor, C., Schmid, M., Germing, U., Kuendgen, A., Rethwisch, V., Ganser, A., Platzbecker, U., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.048231 · Cited by 230 · see citing works
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Sekeres, M. A., Tiu, R. V., Komrokji, R. S., Lancet, J. E., Advani, A. S., Afable, M. G., Englehaupt, R. K., Juersivich, J., Cuthbertson, D. D., Paleveda, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-434639 · Cited by 130 · see citing works
Self-citation
Current therapy of myelodysplastic syndromes
Zeidan, A. M., Linhares, Y. P. L., & Gore, S. D. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.07.003 · Cited by 86 · see citing works
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
Tsai, H., Jiang, S. S., Hung, W.-C., Borthakur, G. M., Lin, S.-F., Pemmaraju, N., Jabbour, E. J., Bomalaski, J. S., Chen, Y., Hsiao, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10542-4 · Cited by 77 · see citing works
The application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76 · see citing works
To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century
Ustun, C., Lazarus, H. M., & Weisdorf, D. J. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.67 · Cited by 75 · see citing works
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Löwenberg, B., Pabst, T., Maertens, J. A., Gradowska, P. L., Biemond, B. J., Spertini, O., Vellenga, E., Griškevičius, L., Tick, L. W., Jongen‐Lavrencic, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003855 · Cited by 69 · see citing works
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Pollyea, D. A., Zehnder, J. L., Coutre, S. E., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O. I., Greenberg, P. L., Zhang, B. M., Liedtke, M., Berube, C., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.076414 · Cited by 65 · see citing works
Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 60 · see citing works
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
Zeidan, A. M., Kharfan‐Dabaja, M. A., & Komrokji, R. S. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000016 · Cited by 60 · see citing works
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines
Nishiguchi, G., Mascibroda, L. G., Young, S. M., Caine, E. A., Abdelhamed, S., Kooijman, J. J., Miller, D. J., Das, S., McGowan, K., Mayasundari, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44698-1 · Cited by 57 · see citing works
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion
List, A., Ebert, B. L., & Fenaux, P. (2018) · Leukemia · doi:10.1038/s41375-018-0029-9 · Cited by 49 · see citing works
Self-citation
Role of tumour angiogenesis in haematological malignancies
Medinger, M., & Passweg, J. R. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14050 · Cited by 42 · see citing works
Acute myeloid leukemia
Johansson, B., & Harrison, C. J. (2015) · Wiley eBooks · doi:10.1002/9781118795569.ch6 · Cited by 42 · see citing works
Burdens, Needs and Satisfaction of Terminal Cancer Patients and their Caregivers
Chang, Y., Kwon, Y. C., Lee, W. J., Do, Y. R., Lee, K. S., Kim, H. T., Park, S. R., Hong, Y. S., Chung, I., & Yun, Y. H. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.1.209 · Cited by 36 · see citing works
Acute Myeloid Leukemia: Focus on novel Therapeutic Strategies
Lin, T. L., & Levy, M. Y. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7244 · Cited by 35 · see citing works
Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process
Zeichner, S. B., & Arellano, M. L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0355-3 · Cited by 35 · see citing works
A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
Chen, Y., Kantarjian, H. M., Estrov, Z. E., Faderl, S., Ravandi, F., Rey, K., Cortes, J. E., & Borthakur, G. M. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.04.001 · Cited by 31 · see citing works
Expanding role of lenalidomide in hematologic malignancies
Ghosh, N., Grunwald, M. R., Fasan, O. O., & Bhutani, M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s81310 · Cited by 30 · see citing works
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
Gbolahan, O. B., Zeidan, A. M., Stahl, M. F., Zaid, M. I. A., Farag, S. S., Paczesny, S., & Koenig, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081660 · Cited by 29 · see citing works
Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia
Tsai, H., Hsiao, H., Hsu, Y., Liu, Y., Kao, H., Liu, T., Cho, S., Feng, X., Johnston, A. L., Bomalaski, J. S., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3871 · Cited by 29 · see citing works
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
Dinardo, C. D., Daver, N. G., Jabbour, E. J., Kadia, T. M., Borthakur, G. M., Konopleva, M. Y., Pemmaraju, N., Yang, H., Pierce, S. A., Wierda, W. G., et al. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)00026-x · Cited by 28 · see citing works
Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison?
Platzbecker, U., & Germing, U. (2013) · Leukemia · doi:10.1038/leu.2013.140 · Cited by 25 · see citing works
Immunomodulating Drugs in Myelodysplastic Syndromes
Adès, L., & Fenaux, P. (2011) · Hematology · doi:10.1182/asheducation-2011.1.556 · Cited by 25 · see citing works
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher‐risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia
Zeidan, A. M., Smith, B. D., Carraway, H. E., Gojo, I., Dezern, A. E., & Gore, S. D. (2016) · British Journal of Haematology · doi:10.1111/bjh.14407 · Cited by 25 · see citing works
Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences
Venugopal, S., Mascarenhas, J. O., & Steensma, D. P. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100735 · Cited by 25 · see citing works
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 26 · see citing works
Myelodysplastic syndromes: toward a risk-adapted treatment approach
Faltas, B. M., Zeidan, A. M., & Gergis, U. S. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2013.840997 · Cited by 24 · see citing works
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
Adès, L., Prébet, T., Stamatoullas, A., Récher, C., Guièze, R., Raffoux, E., Bouabdallah, K. K., Hunault, M., Wattel, E., Stalnikiewicz, L., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151894 · Cited by 24 · see citing works
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies
Statler, A. B., Othus, M. K. D., Erba, H. P., Chauncey, T. R., Radich, J. P., Coutre, S. E., Advani, A. S., Nand, S., Ravandi, F., Mukherjee, S., et al. (2018) · Blood · doi:10.1182/blood-2018-01-826693 · Cited by 24 · see citing works
Self-citation
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
Prébet, T., Cluzeau, T., Park, S., Sekeres, M. A., Germing, U., Adès, L., Platzbecker, U., Götze, K. S. S., Vey, N., Olíva, E. N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18477 · Cited by 21 · see citing works
Self-citation
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
Medeiros, B. C., McCaul, K., Kambhampati, S., Pollyea, D. A., Kumar, R., Silverman, L. R., Kew, A. K., Saini, L., Beach, C., Vij, R., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.172353 · Cited by 22 · see citing works
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes
Palumbo, A. P., Freeman, J., Weiss, L., & Fenaux, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.619975 · Cited by 21 · see citing works
Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
Kubasch, A. S., & Platzbecker, U. (2018) · Cancers · doi:10.3390/cancers10060158 · Cited by 20 · see citing works
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies
Vallet, S., Witzens‐Harig, M., Jaeger, D., & Podar, K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656091 · Cited by 19 · see citing works
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine–lenalidomide combination the way to go?
Zeidan, A. M., Gore, S. D., & Komrokji, R. S. (2013) · Expert Review of Hematology · doi:10.1586/ehm.13.30 · Cited by 18 · see citing works
Lenalidomide as a novel treatment of acute myeloid leukemia
Chen, Y., & Borthakur, G. M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.758712 · Cited by 17 · see citing works
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia
DeAngelo, D. J., Brunner, A. M., Werner, L., Avigan, D., Fathi, A. T., Sperling, A. S., Washington, A., Stroopinsky, D., Rosenblatt, J., McMasters, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.24968 · Cited by 16 · see citing works
IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML
López‐Millán, B., de la Guardia, R. D., Roca-Ho, H., Anguita, E., Islam, A. B. M. M. K., Romero–Moya, D., Prieto, C., Gutiérrez‐Agüera, F., Bejarano-García, J. A., Pérez‐Simón, J. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1477460 · Cited by 16 · see citing works
Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
Prébet, T., Charbonnier, A., Gelsi‐Boyer, V., Mozziconacci, M. J., Blaise, D., & Vey, N. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.744455 · Cited by 14 · see citing works
Novel and Emerging Drugs for Acute Myeloid Leukemia
Stein, E. M., & Tallman, M. S. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912800673248 · Cited by 13 · see citing works
Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience
Heiblig, M., Jeune, C. L., Elhamri, M., Balsat, M., Tigaud, I., Pleșa, A., Barraco, F., Labussière, H., Ducastelle, S., Nicolini, F. E., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1180688 · Cited by 13 · see citing works
Trends in Clinical Investigation for Myelodysplastic Syndromes
Prébet, T., & Zeidan, A. M. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.012 · Cited by 13 · see citing works
Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone
Tamari, R., Schinke, C., Bhagat, T. D., Roth, M. E., Braunschweig, I., Will, B., Steidl, U. G., & Verma, A. K. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.894186 · Cited by 11 · see citing works
Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
Xie, C.-H., Wei, M., Yang, F., Wu, F.-Z., Chen, L., Wang, J., Liu, Q., & Huang, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s168610 · Cited by 11 · see citing works
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 10 · see citing works
“…progressing into AMl and many AMl patients harboring 5q abnormalities, targeting cK1α with lenalidomide showed only a modest therapeutic effect (Sekeres et al. 2011). cK1α is essential for AMl cell survival and yet only a subset of myeloid cell lines were sensitive to lenalidomide (Järås et…”
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities
Dennis, M. W., Culligan, D. J., Karamitros, D., Vyas, P., Johnson, P. R. E., Russell, N. H., Cavenagh, J. D., Szubert, A. J., Hartley, S., Brown, J. M., et al. (2013) · Leukemia Research Reports · doi:10.1016/j.lrr.2013.07.003 · Cited by 9 · see citing works
Lenalidomide in AML: Del(5q) or who?
Steensma, D. P., & Stone, R. M. (2011) · Blood · doi:10.1182/blood-2011-05-354324 · Cited by 9 · see citing works
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide
Loiseau, C., Ali, A., & Itzykson, R. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.014 · Cited by 9 · see citing works
Hypomethylating agents and chemotherapy in MDS
Adès, L., & Santini, V. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.09.010 · Cited by 8 · see citing works
Acute myeloid leukemia in the elderly (age 70 yr or older): long‐term survivors
Heiblig, M., Elhamri, M., Jeune, C. L., Laude, M., Deloire, A., Wattel, E., Salles, G., & Thomas, X. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12811 · Cited by 8 · see citing works
Ultra-Low-Dose Decitabine Combined With Autologous Cytokine-Induced Killer Cells for Elderly Patients With Acute Myeloid Leukemia Transformed From Myelodysplastic Syndrome
Wang, H., Yang, B. Y., Chi, X.-H., Cai, L., Yu, R., Zhu, H., Tuo, S., Zhang, F., Wang, X., Yang, Y., et al. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.065 · Cited by 7 · see citing works
New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies
Norsworthy, K. J., Luznik, L., & Gojo, I. (2012) · Reviews on Recent Clinical Trials · doi:10.2174/157488712802281303 · Cited by 7 · see citing works
Induction and Postremission Strategies in Acute Myeloid Leukemia: State of the Art and Future Directions
Rosenblat, T. L., & Jurcic, J. G. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.007 · Cited by 6 · see citing works
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol
for The Israel Myelodysplastic Syndrome Working Group (MDS-WG), Mittelman, M., Filanovsky, K., Ofran, Y., Rosenbaum, H., Raanani, P., Braester, A., Goldschmidt, N., Kirgner, I., Herishanu, Y., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2776-x · Cited by 6 · see citing works
Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS)
Symeonidis, A. S., Diamantopoulos, P. T., Galanopoulos, A. G., Kourakli, A., Sazakli, E., Hatzimichael, E. C., Pagoni, M. N., Zikos, P., Vassilakopoulos, T. P., Gavriilaki, E., et al. (2025) · Cancers · doi:10.3390/cancers17091388 · Cited by 5 · see citing works
Sequential Azacitidine and Lenalidomide for Patients with Relapsed and Refractory Acute Myeloid Leukemia: Clinical Results and Predictive Modeling Using Computational Analysis
Stevens, B. M., Winters, A. C., Gutman, J. A., Fullerton, A., Hemenway, G., Schatz, D., Miltgen, N., Wei, Q., Abbasi, T., Vali, S., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2019.04.005 · Cited by 5 · see citing works
Revisiting maintenance therapy in acute myeloid leukemia with novel agents
Canaani, J., & Luger, S. M. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000223 · Cited by 5 · see citing works
Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?
Finn, L. E., & Foran, J. M. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000220 · Cited by 4 · see citing works
Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide
Kremer, B. E., Tsai, D. E., Debonera, F., Cohen, P. L., & Schuster, S. J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1347652 · Cited by 4 · see citing works
Innovative strategies for adverse karyotype acute myeloid leukemia
Blum, S., Greve, G., & Lübbert, M. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000318 · Cited by 4 · see citing works
An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia
Kaur, I., Constance, J. E., Kosak, K. M., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.972934 · Cited by 4 · see citing works
Acute Myeloid Leukemia in the Elderly
Thomas, X. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.6 · Cited by 4 · see citing works
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant
Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1635005 · Cited by 4 · see citing works
A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation
Aubrey, B. J., Blonquist, T. M., McMasters, M., Hobbs, G. S., McAfee, S. L., Rosenblatt, J. M., Amrein, P. C., Connolly, C. A., Ramos, A. Y., Logan, E. K., et al. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.107693 · Cited by 3 · see citing works
Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
Rafelson, W., Reagan, J. L., Fast, L. D., & Lim, S. H. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1306646 · Cited by 3 · see citing works
Hypomethylating agent based combinations in higher risk myelodysplastic syndrome
Chandhok, N. S., Lewis, R., & Prébet, T. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1697812 · Cited by 3 · see citing works
Human leukocyte antigen (HLA) alleles as predictive factors for benefit from lenalidomide in acute myeloid leukemia (AML).
Punatar, S. B., Gokarn, A. G., Nayak, L., Bonda, A., Mirgh, S. P., Chichra, A., Singh, M. M., D’Silva, S. Z., & Khattry, N. (2021) · PubMed Central · Cited by 3 · see citing works
De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”
Clavio, M., Cruciani, F., Minetto, P., Guolo, F., Ballerini, F., Marani, C., Astis, E. D., Aquino, S., Bergamaschi, M., Mitscheunig, L., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1780-7 · Cited by 3 · see citing works
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
Saygin, C., Larkin, K. T. M., Blachly, J. S., Orwick, S. J., Ngankeu, A., Gregory, C. T., Phelps, M. A., Mani, S., Walker, A., Garzon, R., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25958 · Cited by 3 · see citing works
The safety of treatment options for elderly people with acute myeloid leukemia
Thomas, X., & Jeune, C. L. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1161020 · Cited by 2 · see citing works
Management of High-Risk Myelodysplastic Syndrome
Zeidan, A. M., & Gore, S. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-36229-3_12 · Cited by 2 · see citing works
LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia
Yoshimura, S., Actis, M., Seffernick, J. T., McGrath, L., Jarusiewicz, J., Aggarwal, A., Li, A., Li, Y., Lee, D. G., Yang, L., et al. (2026) · Blood · doi:10.1182/blood.2025031127 · Cited by 1 · see citing works
Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia by Immunomodulatory and Epigenetic Drugs
Fuchs, O. (2013) · InTech eBooks · doi:10.5772/52099 · Cited by 1 · see citing works
5-Azacitidine in the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
Wanquet, A., Vey, N., & Prébet, T. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.47 · Cited by 1 · see citing works
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia Running Title: Azacitidine plus Lenalidomide for Acute Myeloid Leukemia
Pollyea, D. A., Zehnder, J. L., Coutre, S. E., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O. I., Greenberg, P. L., Zhang, B. M., Liedtke, M., Berube, C., et al. (2012)
Management of acute myeloid leukemia (AML) in elderly and resource constrained setting
Ramanan, V., & Kelkar, K. (2018) · Hematology & Transfusion International Journal · doi:10.15406/htij.2018.06.00160
Dynamics of natural killer cell homeostasis : implications for cell-based cancer Immunotherapy
Pfefferle, A. (2019) · Figshare
Elaboration de nouvelles stratégies d'immunothérapie dans les leucémies aigües
Roy, A. L. (2015) · theses.fr (ABES) · doi:10.70675/fda42f6dz8d29z4ca9za484zccec301cfb1d

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605)
Sekeres, M. A., Gundacker, H. M., Lancet, J. E., Advani, A. S., Petersdorf, S. H., Liesveld, J. L., Mulford, D. A., Norwood, T., Willman, C. L., List, A. F., et al. (2010) · Blood · doi:10.1182/blood.v116.21.332.332 · Cited by 8 · see citing works
Self-citation
Acute Myelogenous Leukemia: Early Indication that Lenalidomide May Help Subset of Elderly Patients
Samson, K. (2011) · Oncology Times · doi:10.1097/01.cot.0000399772.00035.51
Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.
Fehniger, T. A., Nelson, A., Trinkaus, K. M., Abboud, C. N., Cashen, A. F., DiPersio, J. F., Graubert, T. A., Ley, T. J., Tomasson, M. H., Uy, G. L., et al. (2007) · Blood · doi:10.1182/blood.v110.11.916.916 · Cited by 8 · see citing works
Lenalidomide in AML: Del(5q) or who?
Steensma, D. P., & Stone, R. M. (2011) · Blood · doi:10.1182/blood-2011-05-354324 · Cited by 9 · see citing works
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
Fehniger, T. A., Uy, G. L., Trinkaus, K., Nelson, A. D., Demland, J., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., Westervelt, P., DiPersio, J. F., et al. (2011) · Blood · doi:10.1182/blood-2010-07-297143 · Cited by 107 · see citing works

Authors: Sekeres, M. A., Gundacker, H., Lancet, J., Advani, A., Petersdorf, S., Liesveld, J., Mulford, D., Norwood, T., Willman, C. L., Appelbaum, F. R., & List, A. F.
Affiliations: Cleveland Clinic (US)
SWOG Cancer Research Network (US)
Moffitt Cancer Center (US)
Seattle Cancer Care Alliance (US)
University of Rochester (US)
University of Washington (US)
UNM Comprehensive Cancer Center (US)
Fred Hutch Cancer Center (US)
ORCID: Sekeres, Mikkael A.
Lancet, Jeffrey
Advani, Anjali
Liesveld, Jane
Willman, Cheryl L.
Appelbaum, Frederick R.
List, Alan F.
Venue: Blood
Publisher: American Society of Hematology
Published: 2011-07-21
Volume: 118
Issue: 3
Pages: 523-528
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2011-02-337303
PMC: PMC3142897
OpenAlex: W1980451195
Cited by: 80
References: 39
Citations by year: 2026: 1 · 2025: 3 · 2024: 1 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 8 · 2017: 8 · 2016: 9 · 2015: 5 · 2014: 5 · 2013: 15 · 2012: 11
FWCI: 7.88
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Blood (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (2u10ca038926-25)
National Cancer Institute (U10CA004919, CA-11083, CA 20319, N01 CA027057, N01 CA045807, N01 CA038926, CA 42777, N01 CA004919, N01 CA032102, CA-76429, U10-CA038926, U10CA073590, N01 CA067575, U10CA027057, U10CA020319, U10CA011083, CA073590, U10CA076429, U10CA035119, U10CA032102, U10CA042777, U10CA045807, N01 CA046441, N01 CA035119, U10CA067575, U10CA046441)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords: lenalidomide, acute myeloid leukemia, chromosome 5q deletion, elderly patients, myelodysplastic syndrome, monotherapy, induction therapy, maintenance therapy, relapse-free survival, overall survival, complex cytogenetics
MeSH terms: Lenalidomide, Aged, Aged, 80 and over, Antineoplastic Agents, Chromosome Deletion, Chromosomes, Human, Pair 5, Female, Humans, Male, Middle Aged, Thalidomide, Leukemia, Myeloid, Acute, Survival Rate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks